Vier nieuwe bedrijven, waaronder LIFE Cooperative-lid Bioprex Medical, opgericht door onderzoekers van de Faculty of Science & Engineering, zijn genomineerd voor deelname aan de vijfde editie van de Academic Startup Competition (ASC).
De ASC is een jaarlijks programma waarin de meest veelbelovende academische startups meedoen vanuit Nederlandse universiteiten en onderzoeksinstituten. Het doel van de ASC is om hun groei te versnellen, helderheid te bieden over waar hun focus moet liggen en deuren te openen die tot nu toe gesloten waren.
De ASC begint met veertig teams, die zijn voorgedragen door Nederlandse universiteiten, start-up programma’s, onderzoeksinstituten en vanuit onderzoeksprogramma’s. Na drie ronden zullen op 2 april tien winnaars worden aangewezen, die een maand later afreizen naar de VS. Daar ontmoeten deze teams in Silicon Valley ondernemers, investeerders en verbinders.
Bioprex Medical
Medische implantaten, of andere medische hulpmiddelen in het lichaam, zijn gevoelig voor bacteriële infecties. Het is bovendien vaak lastig om zulke infecties te behandelen met antibiotica, waardoor gemakkelijk resistentie bij de bacteriën kan ontstaan.
Wetenschappers van het Zernike Institute for Advanced Materials onder leiding van prof. Ton Loontjes en dr. Rui Li hebben een antibacteriële coating ontwikkeld die dit soort infecties bij medische implantaten kan voorkomen. De coating (die is gebaseerd op zogeheten quaternaire ammonium verbindingen) doodt de bacteriën via een elektrostatisch mechanisme. Dat verschilt sterk van de manier waarop antibiotica werken, dus het gebruik van de coating zorgt niet voor de ontwikkeling van resistentie.
Lees het hele artikel van Rijksuniversiteit Groningen (FSE Science Newsroom | René Fransen) hier verder.
In het Noorden, en Groningen in het bijzonder, zitten tientallen bedrijven die zich bezighouden met innovaties op het gebied van life science en health. Veel pareltjes zitten erbij, zegt Ronald Hesse, directeur van samenwerkingsverband LIFE Cooperative. “Miljoenen patiënten wereldwijd hebben al kunnen profiteren van innovaties die hier in Groningen zijn ontwikkeld”, zegt hij.
Onderzoekers van het UMCG en spin‑off CC Diagnostics, lid van de LIFE Cooperative, hebben een nieuwe test ontwikkeld die het screenen op baarmoederhalskanker mogelijk efficiënter en gebruiksvriendelijker maakt.
A full house, sharp discussions, and an afternoon in which science and industry visibly strengthened one another. The Dutch Medicines Winter Afternoon demonstrated that Groningen is not only a strong geographical spot, but also a substantive force within the Dutch life sciences landscape. The event, organized by FIGON (Federation for Innovative Drug Research Netherlands) in collaboration with LIFE Cooperative, brought professionals from across the Netherlands to the north. Researchers, entrepreneurs, developers, and clinical experts gathered around one shared ambition: to bring innovative medicines to patients faster, smarter, and better.Klaas Poelstra, Chair of FIGON, looks back positively on the event: “It was great to see local businesses in the health sector and leading academic scientists engaging in conversation with one another. They have so much to gain from each other.“From what to how What became particularly clear during the Dutch Medicines Winter Afternoon was how rapidly the field of drug development is evolving, and how essential collaboration has become. At a time when therapies are increasingly targeted, complex, and costly, the focus is shifting from only what we develop to how we do so: more intelligently, more sustainably, and better aligned with patient needs. This broader context was already reflected in the opening remarks by Klaas Poelstra, who emphasized the importance of continued innovation for the Netherlands’ competitive position and patient care. On behalf of the LIFE Cooperative, Robert Hof highlighted that regional collaboration is a decisive factor: by bringing science, entrepreneurship, and clinical practice closer together, real acceleration can be achieved. The first substantive contributions made it clear that innovation today is not only about new molecules, but also about new delivery methods. Rob Steendam demonstrated how long-acting microspheres can improve treatment adherence and reduce patient burden. Jaap Wieling showed how inhalation technology is evolving into a platform for both local and systemic therapies. Through her research on polyelectrolyte coacervates, Marleen Kamperman placed these innovations within a fundamental scientific framework. After the break, the discussion shifted to clinical translation and advanced nanomedicines. Flávia Sousa illustrated how polymer-based nanomedicines contribute to targeted brain delivery. Ad Roffel underscored the importance of robust pharmacokinetic studies in an era where the demands for evidence continue to increase. Erik Frijlink reflected on innovation within both existing and new delivery systems, while Helder Santos outlined the potential of RNA delivery via nanotechnology for cardiac tissue repair.More Than a Program During the closing networking reception, it became clear what participants had gained from the afternoon. As Robert Hof, Board Member of the LIFE Cooperative, put it: “The FIGON Winter Afternoon was an excellent event with distinguished speakers and strong engagement. We look forward to the next edition and extend our sincere thanks to Klaas Poelstra and FIGON for hosting the event in the Northern Netherlands.” The common thread throughout the afternoon was therefore unmistakable: the future of medicines does not lie within a single discipline, but in the connections between them. In a time of increasing healthcare pressure, rapid technological advancement, and international competition, such collaboration is not a luxury, it is a necessity. The Dutch Medicines Winter Afternoon showed that this collaboration is firmly rooted in the Northern Netherlands and that Groningen is positioning itself emphatically as a breeding ground and accelerator for innovative drug development.
